Pacira BioSciences, Inc. (PCRX) Stock Analysis

Pacira BioSciences, Inc. (PCRX) is a publicly traded company in the HEALTHCARE sector. It trades at $22.25, carries a market capitalization of $903.43M, a price-to-earnings ratio of 176.62. This page summarizes the public market data, fundamentals, and frequently asked questions for PCRX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

Market Sentiment

Pacira BioSciences, Inc. currently has a Bullish sentiment score of 0.40.

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. (PCRX) is a pioneering biopharmaceutical company headquartered in Parsippany, New Jersey, dedicated to transforming pain management through innovative non-opioid therapies and regenerative health solutions. By focusing on advanced pain management alternatives, Pacira addresses the critical need for effective solutions that reduce opioid reliance, thereby enhancing patient outcomes and supporting healthcare professionals' practices. With a robust pipeline and a strong ...

GNG Research Analysis

GNG Research scores Pacira BioSciences, Inc. (PCRX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PCRX.

Frequently Asked Questions

Does PCRX pay dividends?

Pacira BioSciences, Inc. (PCRX) does not currently pay a regular dividend.

What is PCRX's P/E ratio?

Pacira BioSciences, Inc. has a price-to-earnings (P/E) ratio of 176.62.

What is PCRX's market cap?

Pacira BioSciences, Inc. (PCRX) has a market capitalization of $903.43M with a current stock price of $22.25.